US equities |
TSLA $396.06 ▲+6.40% MU $902.62 ▲+2.86% SPCX $148.05 ▲+0.38% NVDA $217.15 ▲+2.93% META $645.75 ▲+0.49% SNDK $1,257.58 ▲+1.58% AAPL $346.64 ▼-0.31% AMD $525.56 ▲+1.70%
FinancialContent

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

2.140 -0.100 (-4.46%)
Delayed Quote Updated: 10:56 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in Men’s Fitness Article Examining Unbuzzd Clinical Trial Results
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains FDA Clearance to Test Distinct Approach to MS Treatment
Via Investor Brand Network
News headline image
Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built ↗
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
From Quantum BioPharma
Via GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy 
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO
Via Investor Brand Network
News headline image
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
Via Investor Brand Network
News headline image
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
From Quantum BioPharma
Via GlobeNewswire
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND
Via Investor Brand Network
News headline image
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research
From NetworkNewsWire
Via GlobeNewswire
News headline image
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
From Quantum BioPharma Ltd.
Via GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
From Quantum BioPharma Ltd.
Via GlobeNewswire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >